MA54328A - Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations - Google Patents
Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisationsInfo
- Publication number
- MA54328A MA54328A MA054328A MA54328A MA54328A MA 54328 A MA54328 A MA 54328A MA 054328 A MA054328 A MA 054328A MA 54328 A MA54328 A MA 54328A MA 54328 A MA54328 A MA 54328A
- Authority
- MA
- Morocco
- Prior art keywords
- type
- tgf
- beta superfamily
- receptor heteromultimers
- heteromultimers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562143579P | 2015-04-06 | 2015-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA54328A true MA54328A (fr) | 2021-10-06 |
Family
ID=57072866
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053400A MA53400A (fr) | 2015-04-06 | 2016-04-06 | Hétéromultimères alk7: actriib et leurs utilisations |
MA041916A MA41916A (fr) | 2015-04-06 | 2016-04-06 | Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations |
MA41920A MA41920B1 (fr) | 2015-04-06 | 2016-04-06 | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
MA054328A MA54328A (fr) | 2015-04-06 | 2016-04-06 | Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA053400A MA53400A (fr) | 2015-04-06 | 2016-04-06 | Hétéromultimères alk7: actriib et leurs utilisations |
MA041916A MA41916A (fr) | 2015-04-06 | 2016-04-06 | Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations |
MA41920A MA41920B1 (fr) | 2015-04-06 | 2016-04-06 | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
Country Status (15)
Country | Link |
---|---|
US (7) | US10227392B2 (fr) |
EP (4) | EP3280728B1 (fr) |
JP (3) | JP7055636B2 (fr) |
KR (2) | KR20180002661A (fr) |
CN (4) | CN107709358A (fr) |
AU (4) | AU2016244750B2 (fr) |
BR (1) | BR112017021510A2 (fr) |
CA (2) | CA2981737A1 (fr) |
DK (1) | DK3280728T3 (fr) |
EA (2) | EA037293B1 (fr) |
ES (1) | ES2863564T3 (fr) |
HK (4) | HK1248735A1 (fr) |
MA (4) | MA53400A (fr) |
MX (1) | MX2017012846A (fr) |
WO (2) | WO2016164089A2 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016528295A (ja) | 2013-08-22 | 2016-09-15 | アクセルロン ファーマ, インコーポレイテッド | Tgf−ベータ受容体ii型変異体およびその使用 |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
RS61728B1 (sr) | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Jednograni fuzioni receptorski proteini tipa i i tipa ii i njihove upotrebe |
WO2016164089A2 (fr) | 2015-04-06 | 2016-10-13 | Acceleron Pharma Inc. | Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations |
MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
CA2983440C (fr) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Nouvelles proteines hybrides piegeant le ligand actriib pour le traitement de maladies amyotrophiques |
US9884900B2 (en) | 2015-08-04 | 2018-02-06 | Acceleron Pharma Inc. | Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor |
CN105254764A (zh) * | 2015-08-27 | 2016-01-20 | 上海康岱生物医药技术有限公司 | ACVR1-Fc融合蛋白及其制法和用途 |
US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
DK3496739T3 (da) | 2016-07-15 | 2021-05-10 | Acceleron Pharma Inc | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension |
KR102595559B1 (ko) | 2016-10-05 | 2023-10-30 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
US10934532B2 (en) | 2016-10-05 | 2021-03-02 | Acceleron Pharma Inc. | ALK4.ActRIIB heteromultimers |
CN110198743B (zh) * | 2016-10-05 | 2023-07-18 | 艾科赛扬制药股份有限公司 | 用于治疗肾脏疾病的组合物和方法 |
JP7097354B2 (ja) * | 2016-10-05 | 2022-07-07 | アクセルロン ファーマ インコーポレイテッド | Tgf-ベータスーパーファミリーi型およびii型受容体ヘテロ多量体ならびにその使用 |
KR20240046620A (ko) * | 2016-11-17 | 2024-04-09 | 2세븐티 바이오, 인코포레이티드 | TGFβ 신호 컨버터 |
CA3051696A1 (fr) * | 2017-02-01 | 2018-08-09 | Acceleron Pharma Inc. | Antagonistes de tgf.beta et actrii destines a augmenter l'activite immunitaire |
SI3628049T1 (sl) | 2017-05-04 | 2023-10-30 | Acceleron Pharma Inc. | Fuzijske beljakovine receptorja TGF-beta tipa II in njihova uporaba |
EP3424957A1 (fr) * | 2017-07-03 | 2019-01-09 | advanceCOR GmbH | Protéine de fusion |
MX2020004561A (es) * | 2017-11-02 | 2020-08-13 | Bayer Ag | Anticuerpos biespecificos que se unen a alk-1 y bmpr-2. |
JP2021512919A (ja) * | 2018-02-09 | 2021-05-20 | アクセルロン ファーマ インコーポレイテッド | 異所性骨化を処置するための方法 |
MX2020009272A (es) | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
US20220372107A1 (en) * | 2018-05-03 | 2022-11-24 | Acceleron Pharma Inc. | MULTISPECIFIC BINDERS OF TGFBeta-SUPERFAMILY LIGANDS AND USES THEREOF |
AU2019262143A1 (en) * | 2018-05-03 | 2020-11-26 | Acceleron Pharma Inc. | Novel binders of TGFβ-superfamily ligands and uses thereof |
CA3098679A1 (fr) * | 2018-05-09 | 2019-11-14 | Keros Therapeutics, Inc. | Variants du recepteur de l'activine de type iia et leurs procedes d'utilisation |
EP3797120A1 (fr) | 2018-05-21 | 2021-03-31 | Compass Therapeutics LLC | Compositions et procédés pour améliorer la destruction de cellules cibles par des lymphocytes nk |
WO2019226658A1 (fr) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation |
WO2019241625A1 (fr) * | 2018-06-15 | 2019-12-19 | Acceleron Pharma Inc. | Protéines de fusion bi- et tri-fonctionnelles et utilisations associées |
CN112625137B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白及其医药用途 |
AU2021236249A1 (en) * | 2020-03-13 | 2022-10-06 | Acceleron Pharma Inc. | Single-arm ActRIIA and ActRIIB heteromultimers and methods for treating renal diseases or conditions |
KR102587871B1 (ko) * | 2020-06-19 | 2023-10-12 | 숙명여자대학교산학협력단 | Bmpr2 유전자 기능획득 돌연변이체를 포함하는 돌연변이 복합체 및 이의 용도 |
EP4240388A1 (fr) * | 2020-11-04 | 2023-09-13 | HAN, Hq | Nouveaux antagonistes multispécifiques bifonctionnels capables d'inhiber de multiples ligands de la famille du tgf-bêta et utilisations correspondantes |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0105014B1 (fr) | 1982-09-24 | 1992-05-20 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Rétablissement de tissu chez les animaux |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1990005144A1 (fr) | 1988-11-11 | 1990-05-17 | Medical Research Council | Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
EP1493825A3 (fr) | 1990-06-11 | 2005-02-09 | Gilead Sciences, Inc. | Procédé pour la production de ligands constitués par des acides nucléiques |
US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5707796A (en) | 1990-06-11 | 1998-01-13 | Nexstar Pharmaceuticals, Inc. | Method for selecting nucleic acids on the basis of structure |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992009690A2 (fr) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US20050186593A1 (en) * | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US7592428B1 (en) | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
EP0677104B1 (fr) | 1992-11-17 | 2003-03-19 | Ludwig Institute For Cancer Research | Kinases du type recepteurs activine, proteines possedant des domaines de kinase de serine/threonine et leur utilisation |
US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
US5614609A (en) | 1994-10-20 | 1997-03-25 | Carlos F. Ibanez | Serine threonine kinase receptor |
US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AU716893B2 (en) | 1995-04-11 | 2000-03-09 | General Hospital Corporation, The | Reverse two-hybrid systems |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6699843B2 (en) | 1995-06-07 | 2004-03-02 | Gilead Sciences, Inc. | Method for treatment of tumors using nucleic acid ligands to PDGF |
JPH10303327A (ja) | 1997-04-23 | 1998-11-13 | Yamaichi Electron Co Ltd | 半導体チップの接点変換構造と該接点変換構造を有する半導体チップの製造法 |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6011577A (en) | 1997-06-30 | 2000-01-04 | Polaroid Corporation | Modular optical print head assembly |
JP2001513982A (ja) | 1997-08-29 | 2001-09-11 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | フォリスタチン−3 |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
WO1999029888A1 (fr) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanisation d'anticorps murins |
US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
EP1141708A1 (fr) | 1998-12-28 | 2001-10-10 | Sunesis Pharmaceuticals Inc. | Identification de ligands de type petites molecules organiques, destines a former des liaisons |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
AU772694B2 (en) | 1999-01-21 | 2004-05-06 | Metamorphix International, Inc. | Growth differentiation factor inhibitors and uses therefor |
DE60042021D1 (de) | 1999-07-29 | 2009-05-28 | Gilead Sciences Inc | Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
BR0110610A (pt) | 2000-04-11 | 2003-04-29 | Genentech Inc | Anticorpos isolados, imunoconjugados, cadeias de polipeptìdeos, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo ou cadeia de polipeptìdeos, método de tratamento de disfunções em mamìferos, método de indução da apoptose de uma célula cancerosa, método para matar uma célula b, método para matar uma célula que expresse um receptor de erbb e usos dos anticorpos isolados |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2002239422B2 (en) | 2000-11-30 | 2006-12-07 | E. R. Squibb & Sons, L.L.C. | Transgenic transchromosomal rodents for making human antibodies |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
CA2510003A1 (fr) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Banques de phages anticorps synthetiques |
DE602004022315D1 (de) | 2003-09-15 | 2009-09-10 | Res Dev Foundation | Cripto-antagonismus von activin und tgf-b signalisierung |
US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
US7456149B2 (en) | 2004-03-02 | 2008-11-25 | Acceleron Pharma, Inc. | ALK7 and myostatin inhibitors and uses thereof |
EP1740615B1 (fr) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Anticorps anti-tgf-beta humanises |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP2360186B1 (fr) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anticorps dirigés contre la sélectine P |
US7833971B2 (en) | 2006-12-08 | 2010-11-16 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
EP3059245B1 (fr) | 2004-07-23 | 2018-11-07 | Acceleron Pharma Inc. | Anticorps antagonistes du récepteur actrii |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
PL1791565T3 (pl) | 2004-09-23 | 2016-10-31 | Modyfikowane cysteiną przeciwciała i koniugaty | |
EP1957531B1 (fr) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl |
CN101370511B (zh) * | 2005-11-23 | 2015-07-01 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
PL1973559T3 (pl) | 2005-11-23 | 2013-06-28 | Acceleron Pharma Inc | Antagoniści aktywiny-ActRIIa i zastosowanie do pobudzania wzrostu kości |
WO2007064919A2 (fr) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Polypeptides de liaison avec des sequences de diversite limitees |
JP2009536527A (ja) | 2006-05-09 | 2009-10-15 | ジェネンテック・インコーポレーテッド | 最適化されたスキャフォールドを備えた結合ポリペプチド |
EP2035456A1 (fr) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
WO2008030367A2 (fr) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Inhibiteurs sélectifs de la myostatine |
CN101652387A (zh) * | 2006-11-02 | 2010-02-17 | 阿塞勒隆制药公司 | Alk1受体和配体拮抗剂及其用途 |
EA035911B1 (ru) * | 2006-12-18 | 2020-08-31 | Акселерон Фарма Инк. | Применение полипептида, который ингибирует опосредованный активином сигнальный путь, в качестве лекарственного средства |
TWI548647B (zh) | 2007-02-02 | 2016-09-11 | 艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
CA2681177C (fr) | 2007-03-19 | 2019-08-20 | National Research Council Of Canada | Antagonistes de ligands et leurs utilisations |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法 |
KR20190037355A (ko) * | 2008-05-02 | 2019-04-05 | 악셀레론 파마 인코포레이티드 | 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 alk1 길항제 기재의 방법 및 조성물 |
TWI617316B (zh) | 2008-08-14 | 2018-03-11 | 艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
EP2326670A4 (fr) | 2008-09-17 | 2014-04-16 | Nat Res Council Canada | Agents de liaison hétéro-multivalents pour des membres de la superfamille des tgf- |
KR101778134B1 (ko) | 2008-11-26 | 2017-09-13 | 암젠 인크 | 액티빈 iib 수용체 폴리펩타이드의 변이체 및 이의 용도 |
WO2010083034A1 (fr) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Procédés permettant d'augmenter l'adiponectine |
KR20170134788A (ko) | 2009-03-30 | 2017-12-06 | 악셀레론 파마 인코포레이티드 | Bmp-alk3 길항제 및 골 성장을 촉진시키는 사용되는 이의 용도 |
MX351286B (es) | 2009-06-12 | 2017-10-09 | Acceleron Pharma Inc | Proteinas de fusion actriib-fc truncadas. |
WO2011034605A2 (fr) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Complexes protéiques contenant une super-hélice et/ou une attache et leurs utilisations |
FR2951408B1 (fr) | 2009-10-15 | 2012-01-13 | Renault Sa | Cadre moteur pour moteur electrique de vehicule automobile |
TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
WO2012027065A2 (fr) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Polythérapie pour traiter des maladies |
CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术(上海)有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
WO2013063536A1 (fr) * | 2011-10-27 | 2013-05-02 | Acceleron Pharma, Inc. | AGENTS DE LIAISON À ActRIIB ET UTILISATIONS DE CEUX-CI |
HUE034593T2 (en) | 2012-03-28 | 2018-02-28 | Univ Texas | TGF II-III. types of receptor fusions |
JP2016528295A (ja) | 2013-08-22 | 2016-09-15 | アクセルロン ファーマ, インコーポレイテッド | Tgf−ベータ受容体ii型変異体およびその使用 |
WO2016090035A2 (fr) | 2014-12-02 | 2016-06-09 | La Jolla Institute For Allergy And Immunology | Modulateurs de l'activine et procédés de modulation de réponses immunitaires et de cellules t auxiliaires folliculaires |
WO2016164089A2 (fr) | 2015-04-06 | 2016-10-13 | Acceleron Pharma Inc. | Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations |
RS61728B1 (sr) | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Jednograni fuzioni receptorski proteini tipa i i tipa ii i njihove upotrebe |
MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
CA2983440C (fr) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Nouvelles proteines hybrides piegeant le ligand actriib pour le traitement de maladies amyotrophiques |
WO2016205370A1 (fr) | 2015-06-15 | 2016-12-22 | Santa Maria Biotherapeutics, Inc. | Méthodes d'utilisation de protéines à base du récepteur iib de l'activine |
EP3344660A4 (fr) | 2015-08-31 | 2019-07-03 | National Research Council of Canada | Molécules de fusion d'ectodomaines du récepteur du tgf-b et leurs utilisations |
US20170306027A1 (en) | 2016-04-06 | 2017-10-26 | Acceleron Pharma Inc. | Alk7 antagonists and uses thereof |
JP7159148B2 (ja) | 2016-07-07 | 2022-10-24 | アクセルロン ファーマ インコーポレイテッド | Tgfベータスーパーファミリーホモ多量体およびその使用 |
WO2018009732A1 (fr) | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-activine a et méthodes d'utilisation de ces anticorps dans le traitement de l'hypertension artérielle pulmonaire |
US10934532B2 (en) | 2016-10-05 | 2021-03-02 | Acceleron Pharma Inc. | ALK4.ActRIIB heteromultimers |
JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
-
2016
- 2016-04-06 WO PCT/US2016/000033 patent/WO2016164089A2/fr active Application Filing
- 2016-04-06 EP EP16777229.2A patent/EP3280728B1/fr active Active
- 2016-04-06 CN CN201680033093.5A patent/CN107709358A/zh active Pending
- 2016-04-06 US US15/092,577 patent/US10227392B2/en active Active
- 2016-04-06 DK DK16777229.2T patent/DK3280728T3/da active
- 2016-04-06 KR KR1020177031991A patent/KR20180002661A/ko not_active Application Discontinuation
- 2016-04-06 CA CA2981737A patent/CA2981737A1/fr active Pending
- 2016-04-06 EP EP16777003.1A patent/EP3280435B1/fr active Active
- 2016-04-06 MA MA053400A patent/MA53400A/fr unknown
- 2016-04-06 KR KR1020177031989A patent/KR20180002659A/ko not_active Application Discontinuation
- 2016-04-06 EP EP21161146.2A patent/EP3889171A1/fr active Pending
- 2016-04-06 MX MX2017012846A patent/MX2017012846A/es unknown
- 2016-04-06 CN CN202210568634.1A patent/CN115073610A/zh active Pending
- 2016-04-06 AU AU2016244750A patent/AU2016244750B2/en active Active
- 2016-04-06 AU AU2016246708A patent/AU2016246708B2/en not_active Expired - Fee Related
- 2016-04-06 ES ES16777229T patent/ES2863564T3/es active Active
- 2016-04-06 CN CN201680032890.1A patent/CN107847561B/zh active Active
- 2016-04-06 MA MA041916A patent/MA41916A/fr unknown
- 2016-04-06 MA MA41920A patent/MA41920B1/fr unknown
- 2016-04-06 WO PCT/US2016/026277 patent/WO2016164503A1/fr unknown
- 2016-04-06 BR BR112017021510A patent/BR112017021510A2/pt active Search and Examination
- 2016-04-06 MA MA054328A patent/MA54328A/fr unknown
- 2016-04-06 JP JP2017552155A patent/JP7055636B2/ja active Active
- 2016-04-06 EA EA201792222A patent/EA037293B1/ru not_active IP Right Cessation
- 2016-04-06 EA EA202190016A patent/EA202190016A1/ru unknown
- 2016-04-06 US US15/092,609 patent/US10227393B2/en active Active
- 2016-04-06 EP EP20206064.6A patent/EP3828199A1/fr active Pending
- 2016-04-06 CN CN202210222650.5A patent/CN114736307A/zh active Pending
- 2016-04-06 CA CA2981833A patent/CA2981833A1/fr active Pending
- 2016-04-06 JP JP2017552491A patent/JP7037363B2/ja active Active
-
2018
- 2018-07-04 HK HK18108639.0A patent/HK1248735A1/zh unknown
- 2018-07-04 HK HK18108636.3A patent/HK1248733A1/zh unknown
- 2018-07-30 HK HK18109788.7A patent/HK1250373A1/zh unknown
- 2018-09-26 HK HK18112314.4A patent/HK1252957A1/zh unknown
-
2019
- 2019-01-18 US US16/251,325 patent/US10906958B2/en active Active
- 2019-01-18 US US16/251,935 patent/US11028145B2/en active Active
-
2020
- 2020-11-18 US US16/951,192 patent/US20220396607A1/en not_active Abandoned
- 2020-12-04 AU AU2020281136A patent/AU2020281136A1/en active Pending
-
2021
- 2021-01-27 AU AU2021200492A patent/AU2021200492A1/en active Pending
- 2021-04-15 JP JP2021069060A patent/JP7246618B2/ja active Active
- 2021-04-30 US US17/245,123 patent/US11827689B2/en active Active
-
2023
- 2023-08-21 US US18/236,082 patent/US20240158468A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA54328A (fr) | Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations | |
MA56480A (fr) | Agonistes du récepteur glp-1 et leurs utilisations | |
MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
MA50618A (fr) | Polyrhérapies et leurs utilisations | |
MA41460A (fr) | Agents de liaison à la tnfrsf et leurs utilisations | |
MA55044A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
DK3368572T3 (da) | Anti-pd-1-antistoffer og -sammensætninger | |
ES2976108T3 (es) | Sistemas y métodos de sensor de analito transcutáneo | |
MA43821A (fr) | Pyrimidines et variantes de celles-ci, et leurs utilisations | |
MA43417A (fr) | Agonistes améliorés du récepteur de l'apéline (apj) et leurs utilisations | |
MA46471A (fr) | Protéines actriib à variant et leurs utilisations | |
DK3591944T3 (da) | Anycast-baseret wide area-system til distribueret allokering og belastningsbalancering | |
MA46472A (fr) | Hétéromultimères alk4:actriib et leurs utilisations | |
MA53883A (fr) | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations | |
DK3368534T3 (da) | Valbenazin-ditosylat og polymorfer deraf | |
MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
DK3308111T3 (da) | Belastningsføler og belastningsføler-anlæg | |
MA43567A (fr) | Anticorps pacap et leurs utilisations | |
MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
MA44489A (fr) | Pyrimidines et variants de celles-ci, et leurs utilisations | |
MA46945A (fr) | Exopolysaccharides et leurs utilisations | |
EP3522912A4 (fr) | Hétéromultimères de récepteurs de type i et de type ii de la superfamille des tgf-bêta et leurs utilisations | |
MA41495A (fr) | Composés benzoxaborole et leurs utilisations |